Thai PBS Thai PBS
Long-Acting Antibody treatment to be provided to those suffering immunodeficiency
AI In-brief 16 Sept 07:41

Long-Acting Antibody treatment to be provided to those suffering immunodeficiency

  • Thailand secures 257,500 doses of Long-Acting Antibodies (LAAB) from AstraZeneca to protect immunocompromised individuals from severe COVID-19.
  • The LAAB procurement repurposes funds from an existing AstraZeneca vaccine contract, requiring no additional government budget.
  • Composed of Tixagevimab and Cilgavimab, LAAB are long-acting monoclonal antibodies designed to prevent SARS-CoV-2 from entering human cells.
  • Approved for emergency use in Thailand and globally, LAAB is administered prophylactically to eligible patients and demonstrates 83% effectiveness in reducing severe illness.
Full article
News 1/1
Skip > Skip >

Summarised by AI, which can make mistakes. Check the full article.